Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 15/20 | 0.72 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.50 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.50 |
| ▸ | CPB2 | Q96IY4 | 3/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19756836 | 1.00 | FOLH1 (0.72) | FOLH1RIMKLANAALAD2CPB2EPHX2 | |
| SCHEMBL15762847 | 1.00 | FOLH1 (0.72) | FOLH1RIMKLANAALAD2CPB2EPHX2 | |
| SCHEMBL19360000 | 0.89 | FOLH1 (0.74) | FOLH1RIMKLANAALAD2 | |
| SCHEMBL19788056 | 0.88 | FOLH1 (0.72) | FOLH1RIMKLANAALAD2 | |
| SCHEMBL21321739 | 0.88 | FOLH1 (0.72) | FOLH1RIMKLANAALAD2 | |
| SCHEMBL2742760 | 0.88 | FOLH1 (0.72) | FOLH1RIMKLANAALAD2 | |
| SCHEMBL23839908 | 0.87 | FOLH1 (0.87) | FOLH1RIMKLANAALAD2CPB2 | |
| SCHEMBL14330732 | 0.85 | FOLH1 (0.69) | FOLH1RIMKLANAALAD2EPHX2 | |
| SCHEMBL14549933 | 0.85 | FOLH1 (0.69) | FOLH1RIMKLANAALAD2EPHX2 | |
| SCHEMBL15762848 | 0.85 | FOLH1 (0.60) | FOLH1RIMKLANAALAD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9782493-B2 | Conjugates for treating diseases caused by PSMA expressing cells | ENDOCYTE, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-20170258932-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE INC (US) | 2017-09-14 | — | — | US | disclosed |
| US-9636413-B2 | Conjugates for treating diseases caused by PSMA expressing cells | ENDOCYTE, INC. (US) | 2017-05-02 | — | — | US | disclosed |
| US-20160361376-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE, INC. | 2016-12-15 | — | — | US | disclosed |
| US-20160361433-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE INC (US) | 2016-12-15 | — | — | US | disclosed |
| US-20160361432-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE INC (IN) | 2016-12-15 | — | — | US | disclosed |
| US-20160287731-A1 | Compounds for Positron Emission Tomography | ENDOCYTE, INC | 2016-10-06 | — | — | US | disclosed |
| US-20150297735-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE, INC. | 2015-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160361376-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | FOLH1 1/4885RIMKLA 1649/4885NAALAD2 50/4885 |
| US-20160361432-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | FOLH1 1/4885RIMKLA 1649/4885NAALAD2 50/4885 |
| US-20160361433-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | FOLH1 1/4885RIMKLA 1649/4885NAALAD2 50/4885 |
| US-20170258932-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | FOLH1 1/4885RIMKLA 1649/4885NAALAD2 50/4885 |
| US-20160287731-A1 | Compounds for Positron Emission Tomography | FOLH1, FOLR2, FOLR1 | FOLH1 1/4885RIMKLA 110/4885NAALAD2 67/4885 |
| US-20150297735-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | FOLH1 1/4885RIMKLA 1649/4885NAALAD2 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.